Treatments/clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions were recurrence score (RS)-guided: Analysis by histologic subtype.
Salomon M. Stemmer(Tel Aviv University), Nicky Liebermann(Clalit Health Services), Georgeta Fried(Roche (Switzerland)), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Steven Shak(Genomic Health (United States)), Shulamith Rizel(Rabin Medical Center), Noa Ben Baruch(Kaplan Medical Center), Avital Bareket‐Samish, David Geffen(Ben-Gurion University of the Negev), Beatrice Uziely(Hadassah Medical Center), Ella Evron(Sidney Kimmel Comprehensive Cancer Center), Christer Svedman(Genomic Health (United States)), Kevin Isaacs(Emek Medical Center), Hadassah Goldberg(Bar-Ilan University), Mariana Steiner(Sheba Medical Center), Bella Nisenbaum(Meir Medical Center), Shmuel Klang(Hebrew University of Jerusalem), Ora Rosengarten(Sheba Medical Center), Natalya Karminsky(Wolfson Medical Center), Debbie McCullough(Genomic Health (United States))
Cited by 0
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
|JAMA Oncology|2021|291
DNA methylation of <i>RASSF1A, HIN‐1, RAR‐β, Cyclin D2</i> and <i>Twist</i> in <i>in situ</i> and invasive lobular breast carcinoma
|International Journal of Cancer|2003|251
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
|Journal of Cachexia Sarcopenia and Muscle|2018|107